Plasma SVEP1 Levels Predict Cardiovascular Events in Hypertrophic Cardiomyopathy Beyond Conventional Clinical Risk...

Area of Science:

• Cardiology
• Genetics
• Biomarkers

Background:

• Hypertrophic cardiomyopathy (HCM) is a primary genetic heart condition linked to major adverse cardiovascular events (MACE).
• SVEP1 (Sushi, von Willebrand factor type A, epidermal growth factor, and pentraxin domain containing 1) is a plasma-detectable extracellular matrix protein.
• The prognostic value of plasma SVEP1 in HCM, particularly when combined with NT-proBNP (N-terminal pro-B-type natriuretic peptide), remains unclear.

Purpose of the Study:

• To investigate whether plasma SVEP1 levels improve risk prediction for MACE in patients with HCM.
• To evaluate the added predictive value of SVEP1 to established clinical predictors and NT-proBNP.

Main Methods:

• A multicenter prospective cohort study included 610 HCM patients.
• MACE was defined as heart failure hospitalization or cardiac death.
• Cox proportional hazards models and Lasso-regularized Cox models were used to assess MACE risk and predictive performance, with SVEP1 and NT-proBNP as key variables.

Main Results:

• High SVEP1 levels were associated with increased MACE risk, even in patients with low NT-proBNP.
• The addition of SVEP1 significantly improved the predictive accuracy (C statistics) of models incorporating clinical factors and NT-proBNP.
• The model with clinical factors plus SVEP1 outperformed the model with clinical factors plus NT-proBNP.

Conclusions:

• Plasma SVEP1 is a valuable prognostic biomarker in HCM.
• SVEP1 enhances the predictive capability of current risk stratification models for MACE in HCM patients.
• Incorporating SVEP1 levels can refine prognostication for adverse cardiovascular outcomes in HCM.